Hepatitis B, C and D virus infections and risk of hepatocellular carcinoma in Africa: A meta-analysis including sensitivity analyses for studies comparable for confounders.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
20
03
2021
accepted:
09
01
2022
entrez:
21
1
2022
pubmed:
22
1
2022
medline:
22
2
2022
Statut:
epublish
Résumé
Africa denotes unique facies for hepatocellular carcinoma (HCC) characterized by a conjunction of low sensitization, restricted access to diagnosis and treatment and associated with the highest incidence and mortality in the world. We investigated whether hepatitis B (HBV), C (HCV) and D (VHD) viruses were etiological agents of HCC in Africa. Relevant articles were searched in PubMed, Web of Science, African Index Medicus, and African Journal Online databases, as well as manual searches in relevant reviews and included articles. Analytical studies from Africa evaluating the association between HCC development and HBV, HCV, and HDV were included. Relevant studies were selected, data extracted, and the risk of bias assessed independently by at least 2 investigators. The association was estimated using odds ratios (OR) and their 95% confidence interval (95% CI) determined by a random-effects model. Sources of heterogeneity were determined by subgroup analyses. A total of 36 case-control studies were included. With controls having non-hepatic disease, the overall results suggested a significantly increased risk of HCC in patients with HBV (HBeAg (OR = 19.9; 95% CI = [3.7-105.2]), HBsAg (OR = 9.9; 95%) CI = [6.2-15.6]) and DNA (OR = 8.9; 95% CI = [5.9-13.4]); HCV (Anti-HCV (OR = 9.4; 95% CI = [6.3-14.0]) and RNA (OR = 16.5; 95% CI = [7.8-34.6]); HDV (Anti-VHD, (OR = 25.8; 95% CI = [5.9-112.2]); and HBV/HCV coinfections (HBV DNA/HCV RNA (OR = 22.5; 95% CI = [1.3-387.8]). With apparently healthy controls, the overall results suggested a significantly increased risk of HCC in patients with HBV (HBsAg, (OR = 8.9; 95% CI = [6.0-13.0]); HCV (Anti-HCV, (OR = 7.7; 95% CI = [5.6-10.6]); and HBV/HCV coinfections (HBsAg/Anti-HCV (OR = 7.8; 95% CI = [4.4-13.6]) Substantial heterogeneity and the absence of publication bias were recorded for these results. In Africa, HBV/HCV coinfections and HBV, HCV, and HDV infections are associated with an increased risk of developing HCC. The implementation of large-scale longitudinal and prospective studies including healthy participants to search for early biomarkers of the risk of progression to HCC is urgently needed.
Identifiants
pubmed: 35061846
doi: 10.1371/journal.pone.0262903
pii: PONE-D-21-08686
pmc: PMC8782350
doi:
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0262903Subventions
Organisme : European & Developing Countries Clinical Trials Partnership
ID : EDCTP_TMA2019PF-2705
Pays : Netherlands
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Scand J Gastroenterol. 1993 Apr;28(4):331-4
pubmed: 8387695
J Med Virol. 2007 Sep;79(9):1293-304
pubmed: 17607788
Arch Virol. 2020 Jan;165(1):33-42
pubmed: 31630275
Clin Exp Immunol. 1984 Feb;55(2):355-9
pubmed: 6199140
Infect Agent Cancer. 2009 Oct 08;4:15
pubmed: 19814789
J Natl Cancer Inst. 2009 Aug 5;101(15):1066-82
pubmed: 19574418
Trans R Soc Trop Med Hyg. 2001 Sep-Oct;95(5):487-91
pubmed: 11706655
J Natl Cancer Inst. 1979 Mar;62(3):517-20
pubmed: 84090
Bull World Health Organ. 1975;52(3):293-300
pubmed: 1084799
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
J Med Virol. 1992 Jul;37(3):161-4
pubmed: 1279108
Br Med J (Clin Res Ed). 1986 Nov 22;293(6558):1339-41
pubmed: 3024771
Liver Int. 2015 Sep;35(9):2063-71
pubmed: 26053588
Hepatol Res. 2007 Jul;37(s1):S9-S19
pubmed: 17627641
J Clin Gastroenterol. 2001 Aug;33(2):123-6
pubmed: 11468438
Oncogene. 2005 Sep 1;24(38):5858-67
pubmed: 16007211
Contemp Clin Trials. 2015 Nov;45(Pt A):139-45
pubmed: 26343745
Lancet. 1990 Apr 14;335(8694):873-4
pubmed: 1691422
Evid Based Ment Health. 2019 Nov;22(4):153-160
pubmed: 31563865
Am J Gastroenterol. 2008 Sep;103(9):2254-62
pubmed: 18844615
Asian Pac J Cancer Prev. 2019 Aug 01;20(8):2239-2246
pubmed: 31450890
PLoS One. 2018 May 2;13(5):e0196057
pubmed: 29718992
J Natl Cancer Inst. 1977 May;58(5):1197-200
pubmed: 192895
Int J Cancer. 2018 Aug 15;143(4):869-877
pubmed: 29569722
J Cancer Res Ther. 2016 Dec;12(Supplement):C284-C287
pubmed: 28230038
J Infect Dis. 2007 Jan 1;195(1):5-11
pubmed: 17152003
BMC Cancer. 2014 Nov 29;14:893
pubmed: 25432765
Gastroenterology. 2012 May;142(6):1264-1273.e1
pubmed: 22537432
Carcinogenesis. 2012 Jun;33(6):1219-24
pubmed: 22759751
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Int J Cancer. 2011 Jan 1;128(1):176-84
pubmed: 20232388
Cancer. 2015 Oct 15;121(20):3631-8
pubmed: 26177866
Int J Hyg Environ Health. 2005;208(5):329-39
pubmed: 16217918
Int J Cancer. 1992 Jun 19;51(4):537-41
pubmed: 1318267
Br J Cancer. 2005 Feb 14;92(3):607-12
pubmed: 15685242
J Hepatol. 2020 Sep;73(3):533-539
pubmed: 32151618
Clin Exp Med. 2018 Aug;18(3):421-431
pubmed: 29749584
Afr J Med Med Sci. 2012 Dec;41 Suppl:187-91
pubmed: 23678655
Int J Cancer. 2018 Jun 15;142(12):2471-2477
pubmed: 29388206
Hepatology. 1997 Sep;26(3):740-2
pubmed: 9303506
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
PLoS One. 2021 Apr 15;16(4):e0249831
pubmed: 33857215
Ann Hepatol. 2013 Mar-Apr;12(2):173-82
pubmed: 23396727
Aliment Pharmacol Ther. 2013 Mar;37(5):517-26
pubmed: 23305043
Medicine (Baltimore). 2020 Dec 11;99(50):e23659
pubmed: 33327352
World J Hepatol. 2011 Jan 27;3(1):24-30
pubmed: 21307984
Hepatol Int. 2010 Aug 19;4(4):681-90
pubmed: 21286338
J Natl Cancer Inst. 1977 Jun;58(6):1557-61
pubmed: 68119
Trans R Soc Trop Med Hyg. 1992 Sep-Oct;86(5):552-3
pubmed: 1282278
World J Hepatol. 2010 Feb 27;2(2):65-73
pubmed: 21160975
Trans R Soc Trop Med Hyg. 1997 Jan-Feb;91(1):38-41
pubmed: 9093625
Int J Cancer. 1998 Jan 30;75(3):347-54
pubmed: 9455792
J Viral Hepat. 2000 May;7(3):230-4
pubmed: 10849266
Int Semin Surg Oncol. 2005 Oct 04;2:20
pubmed: 16202160
J Viral Hepat. 2019 Jun;26(6):738-749
pubmed: 30661282
Lancet Glob Health. 2020 Feb;8(2):e180-e190
pubmed: 31862245
J Clin Microbiol. 1978 Apr;7(4):394-5
pubmed: 211144
J Egypt Natl Canc Inst. 2007 Mar;19(1):48-60
pubmed: 18839035
Hepatology. 1998 Jun;27(6):1563-6
pubmed: 9620327
Liver Int. 2012 Feb;32(2):231-40
pubmed: 21745272
Acta Virol. 2012;56(3):235-40
pubmed: 23043603
Trans R Soc Trop Med Hyg. 1987;81(6):994-7
pubmed: 2845609
Liver. 1984 Aug;4(4):275-9
pubmed: 6090857
J Hepatol. 2015 Feb;62(2):363-70
pubmed: 25195548
J Clin Gastroenterol. 2013 Jul;47 Suppl:S2-6
pubmed: 23632345
HPB (Oxford). 2005;7(1):26-34
pubmed: 18333158